Cardiovascular drug - Drug interactions

Cardiology Clinics

Volumn 19, Issue 2, 2001, Pages 215-234

  Anderson, Joe R ^b   Nawarskas, James J ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CLONIDINE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; GUANABENZ; METOPROLOL; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; TICLOPIDINE; VERAPAMIL;

CARDIOVASCULAR DISEASE; COMPLEX FORMATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ADSORPTION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; GASTROINTESTINAL MOTILITY; HIGH RISK POPULATION; INTESTINE FLORA; PH; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW;

EID: 0034986591     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(05)70209-5     Document Type: Article

References (187)

1. Nifedipine-phenytoin interaction
2. Gemfibrozil interaction with warfarin sodium (coumadin)
3. Lovastatin: Warfarin interaction
4. Allopurinol and enalapril: Drug induced anaphylactic coronary spasm and acute myocardial infarction
5. Diltiazem myopathy
6. The effect of enzyme induction on the metabolism of disopyramide in man
7. Interaction between diuretics and indomethacin
8. Mechanism of warfarin potentiation by amiodarone: Dose-and concentration-dependent inhibition of warfarin elimination
9. Interaction between fenofibrate and warfarin
10. The interaction of diltiazem with lovastatin and pravastatin
11. Enhancement by an ACE inhibitor of first-dose hypotension caused by ah α 1-blocker
12. Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin
13. Grapefruit juice-drug interactions
14. Rapid clonidine withdrawal with blood pressure overshoot exaggerated by β-blockade
15. A case of lisinopril-induced lithium toxicity
16. Baycol
17. Quinidine and digoxin: An important interaction
18. Atenolol inhibits the elimination of disopyramide
19. Haemodynamic effects and kinetics of concomitant intravenous disopyramide and atenolol in patients with ischaemic heart disease
20. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors
21. Nicardipine increases cyclosporine blood levels
22. Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine
23. Interaction between clonidine and desipramine in man
24. Decreased bioavailability of digoxin due to hypocholesterolemic interventions
25. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers
26. Clonidine withdrawal
27. Postmarketing surveillance of captopril for hypertension
28. Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients
29. The physiological and pharmacological roles of cytochrome P450 isoenzymes
30. ACC/AHA expert consensus document: Use of sildenafil (viagra) in patients with cardiovascular disease
31. Cyclosporine-amiodarone interaction
32. Cimetidine inhibits renal procainamide clearance
33. Ticlopidine-theophylline interaction
34. Effects of metoprolol and propranolol on theophylline elimination
35. Rhabdomyolysis and renal injury with lovastatin use
36. Interaction between disopyramide and practolol
37. Effect of fluvoxamine on the pharmacokinetics of quinidine
38. Cimetidine and bioavailability of labetalol
39. The effects of enzyme induction and enzyme inhibition of labetalol pharmacokinetics
40. Interactions between non-steroidal anti-inflammatory drugs and antihypertensives and diuretics
41. Bradycardia induced by interaction between quinidine and ophthalmic timolol
42. Heart block in a patient on propranolol and fluoxetine
43. Effect of clinoril (sulindac, msd) sulindac, piroxicam and placebo on the hypotensive effect of propranolol in patients with mild to moderate essential hypertension
44. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes
45. The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine
46. Immediate cardiovascular responses to oral prazosin: Effects of concurrent β-blockers
47. Cimetidine-quinidine interaction
48. Pharmacokinetic evaluation of the digoxin-amiodarone interaction
49. Pharmacokinetics of digoxin alone and in the presence of indomethacin therapy
50. Apparent reduced absorption of gemfibrozil when given with colestipol
51. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone
52. Interaction of amiodarone and diphenylhydantoin
53. Effect of fluoxetine on carvedilol stereo-specific pharmacokinetics in patients with heart failure
54. Prazosin: The first-dose phenomenon
55. Adverse reactions to spironolactone: A report from the Boston collaborative drug surveillance program
56. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin
57. The potentiation of warfarin anticoagulation by amiodarone
58. Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine
59. Clonidine withdrawal and blockade
60. The mechanism of the interaction between amiodarone and warfarin in humans
61. Fluid and electrolyte considerations in diuretic therapy for hypertensive patients with chronic obstructive pulmonary disease
62. The pharmacodynamic and pharmacokinetic interaction of flecainide acetate with propranolol: Effects on cardiac function and drug clearance
63. Increased procainamide plasma concentrations caused by quinidine: A new drug interaction
64. Hypertensive crisis induced by interaction of clonidine with imipramine
65. Myositis and rhabdomyolysis associated with current use of simvastatin and nefazadone
66. Enhanced elimination of warfarin during treatment with cholestyramine
67. Itraconazole greatly increases plasma concentrations and effects of felodipine
68. The amiodarone-digoxin interaction
69. Effect of a grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers
70. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
71. Interaction between warfarin and propafenone in healthy volunteer subjects
72. Itraconazole increases plasma concentrations of quinidine
73. Eprosartan does not affect the pharmacodynamics of warfarin
74. The incidence, magnitude, and time course of the amiodarone-warfarin interaction
75. Disopyramide and phenytoin interaction
76. Interaction of metoprolol, propranolol, and atenolol with concurrent administration of cimetidine
77. Influence of nisoldipine on haemodynamic effects and plasma levels of digoxin
78. Nitrendipine/digoxin interaction
79. Asystole produced by the combination of amiodarone and digoxin
80. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide
81. Interaction between propranolol and propafenone in healthy volunteers
82. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine
83. Cimetidine-amiodarone interaction
84. The effects of oral propranolol, digoxin and combination therapy on the resting and exercise electrocardiogram
85. Theophylline toxicity after propafenone treatment: Evidence for drug interaction
86. Sinus arrest and hypotension with combined amiodarone-diltiazem therapy
87. Single dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers
88. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole
89. Amiodarone and β-adrenergic blockers: An interaction with metoprolol but not with atenolol
90. Lescol
91. Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy
92. Verapamil inhibits cyclosporin metabolism
93. Lipitor
94. 2 agonist and a nonselective β antagonist on theophylline clearance
95. Effect of cimetidine on quinidine bioavailability
96. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine
97. Amiodarone-cyclosporine interaction in cardiac transplantation
98. Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure
99. Interaction between warfarin sodium and amiodarone
100. Disopyramide-phenytoin interaction
101. Possible interaction between amiodarone and phenytoin
102. Dose-dependence of atenolol-ampicillin interaction
103. Rhabdomyolysis in patients treated with simvastatin/cyclosporine: Role of the hepatic cytochrome P450 enzyme
104. Mevacor
105. Update: Clinically significant cytochrome P-450 drug interactions
106. Clinical pharmacokinetics of fibric acid derivatives (fibrates)
107. Adverse effects of combined propranolol and chlorpromazine therapy
108. Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man
109. Quinidine-enhanced β-blockade during treatment with propafenone in extensive metabolizer human subjects
110. Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in health volunteers
111. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
112. 2-receptor antagonists and β adrenoceptor blockers
113. Amiodarone-digoxin interaction: Clinical significance, rime course, of development, potential pharmacokinetic mechanisms and therapeutic implications
114. Pharmacokinetic and pharmacodynamic interactions between furosemide and hydrochlorothiazide in nephrotic patients
115. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure?
116. Amiodarone-cyclosporine interaction in heart transplant patient
117. Effect of phenytoin on serum disopyramide concentrations
118. Acceleration of amiodarone elimination by cholestyramine
119. Inhibition by fluoxetine of cytochrome P450 2D6 activity
120. Influence of spironolactone on serum digoxin concentration
121. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia
122. Digoxin-verapamil interaction
123. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients
124. Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol
125. Viagra
126. Myopathy and rhabdomyolysis associated with lovastatingemfibrozil combination therapy
127. Digitoxinquinidine interaction: Potentiation during administration of cimetidine
128. Pravachol
129. Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine
130. The effect of ibuprofen on serum digoxin concentrations
131. Potentially fatal interaction between erythromycin and disopyramide
132. The diltiazem-digoxin interaction
133. Antagonism between non-steroidal anti-inflammatory drugs and diuretics
134. Lovastatin, nicotinic acid, and rhabdomyolysis
135. Cimetidine increases steady state plasma levels of propranolol
136. Phenytoin toxicity associated with ticlopidine administration
137. Asystole and bradycardia during dipyridamole stress testing in patients receiving β-blockers
138. The digoxin-amiodarone interaction
139. Use of labetalol in hypertensive patients during discontinuation of clonidine therapy
140. Effect of amiodarone on serum quinidine and procainamide levels
141. Reduced induction of drug metabolism in the elderly
142. The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients
143. Fever, myalgia, and arthralgia in a patient on captopril and allopurinol
144. Effects of amiodarone on oral and intravenous digoxin kinetics in healthy subjects
145. Atenolol interaction with aspirin, allopurinol, and ampicillin
146. Renal function and digoxin clearance during quinidine therapy
147. Metoprolol pharmacodynamics and quinidine-induced inhibition of polymorphic drug metabolism
148. Loss of stereoselective metoprolol metabolism following quinidine inhibition of P450IID6
149. Drug-interaction-induced rhabdomyolysis
150. Digitalis toxicity and hypomagnesemia
151. Amiodarone-phenytoin interaction
152. Flecainide and amiodarone interaction
153. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences
154. Elevation of thioridazine plasma levels by propranolol
155. The effect of quinidine on the analgesic effect of codeine
156. Influence of cimetidine on verapamil kinetics and dynamics
157. Ranitidine and cimetidine; drug interactions with single and steady-state nifedipine administration
158. Clinical and medicoeconomic impact of the cyclosporinediltiazem interaction in renal transplant recipients
159. Cimetidineprocainamide pharmacokinetic interaction in man: Evidence of competition for tubular secretion of basic drugs
160. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans
161. Possible theophylline-amiodarone interaction
162. Rhabdomyolysis associated with lovastatin and erythromycin use
163. Propafenone-theophylline interaction
164. Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy
165. Clonidine withdrawal complicated by amitriptyline therapy
166. Withdrawal of antihypertensive therapy
167. Altered pharmacokinetics of oral flecainide by cimetidine
168. Potential interaction between warfarin and fluvastatin
169. Increased quinidine plasma concentrations during administration of verapamil: A new quinidine-verapamil interaction
170. Quinidine-nifedipine interaction
171. Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine
172. Inhibition of propranolol metabolism by chlorpromazine
173. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide
174. Interaction of cyclosporin and calcium antagonists
175. Drug interaction between propafenone and metoprolol
176. Interaction of metoprolol and fluoxetine
177. Pharmacokinetics and pharmacodynamics of verapamil in combination with atenolol, metoprolol and propranolol
178. Amiodarone reduces plasma warfarin clearance in man
179. Pharmacokinetic and electrophysiologic interaction of amiodarone and procainamide
180. The effect of ranitidine and cimetidine on single-dose diltiazem pharmacokinetics
181. Alteration of propranolol pharmacokinetics and pharmacodynamics by quinidine in man
182. Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol
183. Zocor